Dow to develop obesity treatment

APRIL 01, 2004
Susan Farley

In a collaborative arrangement, Dow Chemical Company and NOBEX Corporation will develop a new plant-based peptide to serve as an appetite suppressant to treat obesity. Dow's research has traditionally focused on antibodies, but according to NOBEX director Radha Krishnan, PhD, "Their plantbased approach appealed to us because of the prospects for lower costs, higher expression levels, and higher volume production." The expression of the peptide is expected to take place in plant cell suspension. Once that is successful, the production will be increased and later conjugated to oral administration. Because of the increasing numbers of obese patients in the United States, the manufacturers anticipate a large demand for commercial use.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.